updat model ghdx result chang
market expens test volum forecast
forecast make sever modest financi model revis includ
refin estim ghdx contribut oper reduc
expect market cost relat co-promot agreement
updat test volum growth methodolog better captur chang order
pattern exist user test volum estim larg unchang refer
page revis incom statement
reduc sell expens expens unchang
reduc estim
forecast reduc
year price histori
exact scienc corp molecular
diagnost compani initi focu
earli detect prevent
analyst certif import disclosur see disclosur
leverag offer pend acquisit genom health
see upsid consensu ep estim
base potenti upsid merger synergi target
end continu healthi uptak cologuard
visibl futur busi develop
believ strateg rational acquir addit
product sell ghdx medic oncolog distribut
merger ghdx close decemb
exce target ghdx merger synergi end
insur provid coverag zero co-pay patient
econom contribut end
novemb ghdx sharehold vote merger transact
addit granular potenti oper synergi
bolt-on acquisit provid access technolog expand
pipelin boost top line
portion laboratori oper redwood citi realloc
madison anoth low-cost locat
pipelin program make econom contribut
prior end
bolt-on transact result upsid revenu outlook
cologuard offer signific reduct cog support
commerci certain countri outsid us
fail close ghdx transact end
compani unabl achiev expect merger synergi
cologuard fail maintain uspstf rate result potenti
one compani success commerci blood-
base colorect cancer screen test compar better
perform profil cologuard
price target base ev-to-sal analysi assum multipl pro forma estim revenu
million post-merg share outstand multipl peer group high-growth diagnost compani multipl
around due scale commerci infrastructur extend histori oper effici
risk includ merger integr issu aris purchas ghdx cologuard maintain rate
uspstf result patient receiv cologuard zero co-pay blood-bas test make stool-bas test
technolog cologuard obsolet new product adopt includ liquid biopsi take longer current forecast
compani report oppenheim co inc estim
million except per test research sale profit incom profit loss per share gain incom loss loss per share averag common analysisgross exact scienc corpor
